Industries > Pharma > Meningococcal Vaccines Market Report 2021-2031

Meningococcal Vaccines Market Report 2021-2031

Forecasts by Vaccine Type (Conjugate, Polysaccharide, Others), by End-user (Paediatric, Adult, Traveler), by Brand (Bexsero, Menactra, Menveo, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 30 September 2021
PAGES: 373
PRODUCT CODE: PHA0941
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0941 Categories: , Tags: , , , , ,

Global Meningococcal Vaccines Market 2021-2031 – our new study reveals latest industry trends, R&D progress, and predicted revenues
Visiongain understands that the Global Meningococcal Vaccines Market will register robust growth. Increasing prevalence of meningitis, increasing initiatives by government and regulatory authorities, presence of non-profit organizations providing funds for research projects and vaccine trials and are expected to commercialized during the forecast period consequently driving the meningococcal vaccines market by 2031. Meningococcal vaccines market is highly competitive with presence of well-established players with limited scope of regional manufacturers for vaccine platforms. Although, the meningococcal vaccine market will exhibit significant growth during the forecast period, increasing inclusion in NIPs (National Immunization Programs) is unlocking new window of opportunities for meningococcal vaccines worldwide.

Conjugate Segment valued US$x million in 2021 is set to grow at a CAGR of xx% from 2021-2031. Owing to its key benefits such as longer lasting immunity along with its capability to bring herd immunity continues to drive the growth of this segment. Additionally, many key players have several meningococcal conjugate vaccine products in their pipeline and is expected to have significant opportunities for the growth during the forecast period.

By end user, the pediatric segment accounted for the largest market share of 66% in 2021 and is poised to foresee rapid growth during the forecast period due to upsurge in adoption of meningococcal vaccine in several countries across the globe as a part of national immunization programs.

North America continues to retain its hold on meningococcal vaccines market and accounted to have the largest market of 44.2% in 2021. Well-established healthcare infrastructure, developed economy, presence of leading pharmaceutical industry are major factors responsible for sustained growth in this region. The Asian region is expected to foresee the highest growth of 7.3% during the forecast period owing various factors such as increasing healthcare expenditure, increasing disposable income, government initiatives, and the presence of a large patient population. Our report keeps you informed and up to date with latest developments across geographies including North America, Europe, Asia, Latin America and Middle East and Africa.

The report also captures information pertaining to latest mergers & acquisitions, technological innovations, geographical expansion plans of all the leading players of this industry. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The report provides in-depth information of key investment trends in global meningococcal vaccines market, subdivided by type of vaccines type, end user and vaccine brand.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com

This report will answer questions such as:
• What is the meningococcal vaccines market status in 2021 and how it will evolve through 2031?
• What are the drivers, restraints, and opportunities of the meningococcal vaccines market?
• How will each meningococcal vaccines submarket segment grow over the forecast period and how much revenue will each segment account for in 2031?
• How will individual leading national markets perform over the forecast period, and what are their drivers and restraints?
• What have been the major developments of the leading national markets for meningococcal vaccines market over recent years, leading to their current market status?
• How will the market shares of the regional and leading national markets evolve by 2031, and which geographical region will lead in 2031?

Reasons Why You Must Order and Read This Report Today:

The Report provides Meningococcal Vaccines Market By Vaccine Type
• Conjugate
• Polysaccharide
• Others

The Report provides Meningococcal Vaccines Market By End User
• Pediatric
• Adult
• Travelers

The Report provides Meningococcal Vaccines Products Market By Vaccine Brand
• Bexsero
• Menactra
• Menveo
• Others

CTA

Report Covers Regional Analysis

North America meningococcal vaccines Market
• US meningococcal vaccines Market
• Canada meningococcal vaccines Market

Europe meningococcal vaccines Market
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia meningococcal vaccines Market
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia

Latin America meningococcal vaccines Market
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa meningococcal vaccines Market
• GCC
• South Africa
• Rest of Latin America

Meningococcal Vaccines Market Report 2021-2031
Need industry data? Please contact us today.

The report provides detailed profiles of the leading companies operating within the Meningococcal Vaccines market:
• Sanofi, Merck & Co., Inc.
• GlaxoSmithKline plc.
• Pfizer Inc.
• Serum Institute of India Pvt. Ltd.
• Zhi Fei Biological
• Hualan Biological Engineering Inc
• Incepta Pharmaceuticals Ltd.
• Walvax Biotechnology Co., Ltd.
• BIO-MED
• JN International Medical Corporation

Our report captures in-depth analysis of meningococcal vaccines market within total 374 pages with 256 tables and 255 figures. The study helps all the stakeholders to discover and understand this lucrative meningococcal vaccines market with respect to financial results, trends, opportunities and identify business opportunities.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Meningococcal Vaccines Market Report 2021-2031: Forecasts by Vaccine Type (Conjugate, Polysaccharide, Others), by End-user (Paediatric, Adult, Traveler), by Brand (Bexsero, Menactra, Menveo, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Meningococcal Vaccines Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Meningococcal Vaccines Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Liposomal Drug Delivery Devices Market Report 2022-2032

Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.

21 June 2022

READ

Visiongain Publishes Nanotechnology in Drug Delivery Market Report 2022-2032

The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.

20 June 2022

READ

Visiongain Publishes Respiratory Drug Delivery Technologies Market Report 2022-2032

The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.

15 June 2022

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2022-2032

The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.

14 June 2022

READ

Categories